The development of potent, specific, and pharmacologically viable chemical probes and
therapeutics is a central focus of chemical biology and therapeutic development. However, a …

Intracellular protein–protein interactions (PPIs) are challenging targets for traditional drug
modalities. Macrocyclic peptides (MPs) prove highly effective PPI inhibitors in vitro and can …

The effort to modulate challenging protein targets has stimulated interest in ligands that are
larger and more complex than typical small-molecule drugs. While combinatorial techniques …

The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor
bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated …

Bicyclic peptides, a class of polypeptides with two loops within their structure, have emerged
as powerful tools in the development of new peptide drugs. They have the potential to bind …

Increasing disease-related proteins have been identified as novel therapeutic targets.
Macrocycles are emerging as potential solutions, bridging the gap between conventional …

Miniproteins are a diverse group of protein scaffolds characterized by small (1–10 kDa) size,
stability, and versatility in drug-like roles. Coming largely from native sources, they have …

Cancer remains a leading health concern threatening lives of millions of patients worldwide.
Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly …

Tyrosine phosphorylation is a critical component of signal transduction for multicellular
organisms, particularly for pathways that regulate cell proliferation and differentiation. While …

The signal transducer and activator of transcription 3 (STAT3) protein is constitutively
activated in several cancers. STAT3 activity can be blocked by inhibiting its Src Homology 2 …